213 related articles for article (PubMed ID: 33094918)
1. A Heart-Breast Cancer-on-a-Chip Platform for Disease Modeling and Monitoring of Cardiotoxicity Induced by Cancer Chemotherapy.
Lee J; Mehrotra S; Zare-Eelanjegh E; Rodrigues RO; Akbarinejad A; Ge D; Amato L; Kiaee K; Fang Y; Rosenkranz A; Keung W; Mandal BB; Li RA; Zhang T; Lee H; Dokmeci MR; Zhang YS; Khademhosseini A; Shin SR
Small; 2021 Apr; 17(15):e2004258. PubMed ID: 33094918
[TBL] [Abstract][Full Text] [Related]
2. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients.
Haupt LP; Rebs S; Maurer W; Hübscher D; Tiburcy M; Pabel S; Maus A; Köhne S; Tappu R; Haas J; Li Y; Sasse A; Santos CCX; Dressel R; Wojnowski L; Bunt G; Möbius W; Shah AM; Meder B; Wollnik B; Sossalla S; Hasenfuss G; Streckfuss-Bömeke K
Basic Res Cardiol; 2022 Mar; 117(1):13. PubMed ID: 35260914
[TBL] [Abstract][Full Text] [Related]
4. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
5. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
Hsu WT; Huang CY; Yen CYT; Cheng AL; Hsieh PCH
Theranostics; 2018; 8(12):3176-3188. PubMed ID: 29930721
[No Abstract] [Full Text] [Related]
6. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Wei J; Klimberg VS
Ann Clin Lab Sci; 2017 Mar; 47(2):115-119. PubMed ID: 28442511
[TBL] [Abstract][Full Text] [Related]
8. Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients.
Pestana RMC; Teixeira-Carvalho A; Dos Santos LI; de Oliveira AN; Soares CE; Sabino AP; Simões R; Gomes KB
Int J Cardiol; 2024 Jan; 395():131435. PubMed ID: 37852542
[TBL] [Abstract][Full Text] [Related]
9. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
Chang WT; Lin YW; Ho CH; Chen ZC; Liu PY; Shih JY
Arch Toxicol; 2021 Feb; 95(2):659-671. PubMed ID: 33211168
[TBL] [Abstract][Full Text] [Related]
11. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
13. Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients.
Hasan D; Ismail Y; Al Tibi A; Al-Zeidaneen SA; Odeh M; Burghel GJ; Natsheh I; Abdelnour A
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3355-3363. PubMed ID: 34711013
[TBL] [Abstract][Full Text] [Related]
14. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
15. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
16. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
[TBL] [Abstract][Full Text] [Related]
17. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study.
Jacob S; Pathak A; Franck D; Latorzeff I; Jimenez G; Fondard O; Lapeyre M; Colombier D; Bruguiere E; Lairez O; Fontenel B; Milliat F; Tamarat R; Broggio D; Derreumaux S; Ducassou M; Ferrières J; Laurier D; Benderitter M; Bernier MO
Radiat Oncol; 2016 Apr; 11():54. PubMed ID: 27056179
[TBL] [Abstract][Full Text] [Related]
18. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.
Dhingra R; Rabinovich-Nikitin I; Rothman S; Guberman M; Gang H; Margulets V; Jassal DS; Alagarsamy KN; Dhingra S; Valenzuela Ripoll C; Billia F; Diwan A; Javaheri A; Kirshenbaum LA
Circulation; 2022 Sep; 146(12):934-954. PubMed ID: 35983756
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Abrahams C; Woudberg NJ; Lecour S
Lipids Health Dis; 2022 Sep; 21(1):85. PubMed ID: 36050733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
